Johanna Roberts Sells 600 Shares of Penumbra, Inc. (NYSE:PEN) Stock

Penumbra, Inc. (NYSE:PEN) EVP Johanna Roberts sold 600 shares of the firm’s stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $269.11, for a total transaction of $161,466.00. Following the completion of the transaction, the executive vice president now directly owns 66,353 shares of the company’s stock, valued at approximately $17,856,255.83. The trade was a 0.90 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Johanna Roberts also recently made the following trade(s):

• On Monday, March 3rd, Johanna Roberts sold 600 shares of Penumbra stock. The stock was sold at an average price of $287.43, for a total transaction of $172,458.00.

Penumbra Price Performance

Shares of PEN opened at $262.37 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.01 and a quick ratio of 3.25. Penumbra, Inc. has a 1-year low of $148.00 and a 1-year high of $310.00. The stock has a market cap of $10.11 billion, a PE ratio of 771.66, a price-to-earnings-growth ratio of 2.83 and a beta of 0.51. The firm has a fifty day moving average price of $274.48 and a 200 day moving average price of $245.61.

Penumbra (NYSE:PEN) last posted its earnings results on Tuesday, February 18th. The company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.09. The business had revenue of $315.52 million during the quarter, compared to the consensus estimate of $311.63 million. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. As a group, sell-side analysts anticipate that Penumbra, Inc. will post 3.67 EPS for the current year.

Institutional Investors Weigh In On Penumbra

Several large investors have recently modified their holdings of the company. UMB Bank n.a. increased its holdings in shares of Penumbra by 57.4% in the 4th quarter. UMB Bank n.a. now owns 192 shares of the company’s stock valued at $46,000 after acquiring an additional 70 shares during the period. Hurley Capital LLC acquired a new stake in Penumbra during the 4th quarter worth $56,000. Huntington National Bank grew its position in Penumbra by 138.7% during the 4th quarter. Huntington National Bank now owns 265 shares of the company’s stock worth $63,000 after purchasing an additional 154 shares during the last quarter. Mather Group LLC. increased its stake in Penumbra by 208.0% in the fourth quarter. Mather Group LLC. now owns 308 shares of the company’s stock valued at $73,000 after purchasing an additional 208 shares during the period. Finally, Versant Capital Management Inc raised its holdings in shares of Penumbra by 893.5% in the first quarter. Versant Capital Management Inc now owns 308 shares of the company’s stock valued at $82,000 after buying an additional 277 shares during the last quarter. 88.88% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PEN has been the topic of a number of recent research reports. Bank of America initiated coverage on Penumbra in a research report on Friday, March 14th. They set a “buy” rating and a $320.00 price objective on the stock. Robert W. Baird increased their price target on Penumbra from $305.00 to $328.00 and gave the company an “outperform” rating in a research report on Wednesday, February 19th. Piper Sandler reiterated an “overweight” rating and issued a $330.00 price objective (up previously from $250.00) on shares of Penumbra in a research note on Wednesday, February 19th. Truist Financial upped their target price on shares of Penumbra from $285.00 to $325.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. Finally, StockNews.com cut shares of Penumbra from a “buy” rating to a “hold” rating in a report on Friday, February 28th. Four analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $294.47.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.